PULMONARY-DISEASE DURING THE TREATMENT OF RHEUMATOID-ARTHRITIS WITH LOW-DOSE PULSE METHOTREXATE
PULMONARY-DISEASE DURING THE TREATMENT OF RHEUMATOID-ARTHRITIS WITH LOW-DOSE PULSE METHOTREXATE
复制标题
DOI：
10.1016/0049-0172(87)90021-7
复制
发表时间：
1987-02-01
影响因子：
5
通讯作者：
CLEGG, DO
中科院分区：
文献类型：
--
作者：
CARSON, CW;CANNON, GW;CLEGG, DO
甲氨蝶呤治疗类风湿关节炎是有效的，短期经验表明没有严重的不良反应。我们对168例接受甲氨蝶呤治疗的患者进行了回顾，确定了9例患者可能或可能存在甲氨蝶呤引起的肺毒性，患病率为5%，发病率为每年每100例患者3.9例。没有临床或实验室特征显示可能预测肺部疾病发展的关联。所有患者均在支持性护理和/或皮质类固醇治疗下完全康复。在所有接受长期甲氨蝶呤治疗RA的患者中，对这种并发症的临床监测是必要的。
Methotrexate therapy has been effective in the treatment of RA with short term experience suggesting little serious adverse reactions. Our review of 168 patients receiving methotrexate has identified nine patients with probable or possible methotrexate-induced pulmonary toxicity, giving a prevalence of 5% and an incidence of 3.9 per 100 patients per year. No clinical or laboratory features showed an association that could potentially predict the development of pulmonary disease. All patients experienced complete recovery with supportive care and/or corticosteroid therapy. Clinical monitoring for this complication is warranted in all patients receiving long term methotrexate therapy for RA.